Skip to main content

Table 1 Characterization of sarcoidosis patients and HC

From: Reduced expression of peroxisome proliferator-activated receptor alpha in BAL and blood T cells of non-löfgren’s sarcoidosis patients

 

Löfgren’s

Non-Löfgren’s

Healthy controls

Subjects number

27

30

29

Age

39 (28–56)****

47 (27–71)****

26 (18–42) ¤

Sex, female/male

15/12

9/21

15/14

smoking history (NS/FS/OS/CS)

20/5/2/0

16/13/1/0

29/0/0/0

Radiograph stages (0,I, II, III, IV, ND)

0/16/9/0/0/2

0/7/9/4/4/6

29/0/0/0/0

HLA (DR3+/DR3-/ND)

20/6/1

3/24/3

ND

BAL analysis

   

Recovery %

68 (44–80)

63,5 (44–84)

72 (34–88)

Viability %

95 (85–99)

95 (78–98)

95 (88–98)

Cell concentration (*106/L)

225 (49–588)****

188 (83,5-476)****

90,5 (29–167) ¤

Total cell number (*106)

36 (9–77)****

28 (10–81)***

16 (5–31,5) ¤

BAL differential cell counts

   

% Macrophages

68 (39,4-91)****

71 (39,70-85)****

87 (60,8-97,2) ¤

% Lymphocytes

30 (8,5-57,8)****

26 (13–58,2)****

11 (2,4-33,7) ¤

% Neutrophils

1,0 (0–5,8)

1,0 (0–6)

1,8 (0,2-6)

% Eosinophils

0,3 (0–2,5)

0,3 (0–4,4)

0,2 (0–1,6)

CD4/CD8 ratio

9,6 (1,1-28)****

5,8 (1,6 -33)***

2,65 (0,9-4,8) ¤

Pulmonary function tests

   

FVC (% of predicted value)

90 (67–120)****

84 (50–105)****

111 (86–130) ¤

FEV1 (% of predicted value)

87 (61–104)***

82 (46–112)****

107 (86–125) ¤

TLC (% of predicted value)

92 (82–123)**

85 (62–186) #

ND

DLCO (% of predicted value)

86 (66–126)

82 (54–130)

ND

  1. Data are presented as median (minimum-maximum). NS: never smoker, FS: former smoker, OS: occasional smoker, CS: current smoker. Radiographic stages 0: normal, stage I: bilateral hilar lymphadenopathy (BHL), stage II: BHL and parenchymal infiltrates, stage III: parenchymal infiltrates without BHL, stage IV: signs of fibrosis. BAL: bronchoalveolar lavage; VC: vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; ND: not determined; ¤ Kruskal-Wallis test was used to compare all three groups and a significant difference was only observed when LS and non-LS patients were compared with HC; # Mann–Whitney U-test between LS and non-LS patients; **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.